Clinical Trial Update: Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma [EARLY_Phase 1]

View source ↗

Summary

This early-phase proof-of-concept trial of the endothelin receptor B inhibitor BQ-788 for melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BQ-788 (BQ-788)

Snippet

Sponsor: MelCure SA | Conditions: Melanoma | EARLY_Phase 1 | Status: TERMINATED